Focal therapy treatment is now an option to treat low grade prostate cancer in the U.K.
Prostate cancer is the most commonly diagnosed cancer in men and the third commonest cause of cancer related death in Europe.
Serial PSA testing is one way of checking for prostate cancer and can be followed up if an increasing PSA causes suspicion, with a 3T MRI scan that accurately locates a possible cancer. If a targeted biopsy demonstrates a low Gleeson score with no involvement outside the prostate gland, then focal therapy can be considered as a treatment option.
Focal therapy can be either HIFU or Cryotherapy and targeting just the lesion, without damaging other local structures.
The post -operative incidence of bladder problems and erectile dysfunction is low.
At present NICE guidelines do not recommend the above treatment for prostate cancer, except as part of a controlled clinical trial.
Observational studies from the Boston Study suggest that daily orgasm could reduce the incidence of prostate cancer.
Men who ejaculated 21 times/month were at a 22% lower risk of developing prostate cancer.
The above observation was also corroborated by Professor Arver of Karolinska University Hospital Sweden at the World Congress on Aging Males held in Prague in October 2015.